News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Daniel Pollyea, MD, MS, University of Colorado Denver

Articles by Daniel Pollyea, MD, MS, University of Colorado Denver

Optimal Use of Venetoclax in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

VIALE Studies in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

Utilization of Second-Generation FLT3 Inhibitors in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

Second-Generation FLT3 Inhibitors in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

FLT3-Mutated AML: Midostaurin and Chemotherapy

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

FLT3-Mutated AML: Early Aggressive Therapy vs Transplant

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

FLT3 Genetic Alterations in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

Trending on OncLive

Epcoritamab Plus Lenalidomide/Rituximab Win EU Approval for R/R Follicular Lymphoma

FDA Issues CRL to Orviglance for Liver Metastasis Imaging in Patients With Severe Kidney Impairment

Adagrasib Plus Cetuximab Misses OS, PFS End Points in Pretreated KRAS G12C–Mutated CRC

Phase 1 Data Highlight Potential Utility for In Vivo CAR T-Cell Therapy in R/R Myeloma

Dr Spencer on Differentiating Factors for In Vivo CAR T-Cell Therapy in Myeloma